Jose Alexandre de Souza Crippa
Overview
Explore the profile of Jose Alexandre de Souza Crippa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morphine-induced side effects can be differentially modulated by cannabidiol in male and female rats
Jesus C, Volpe J, Sotomaior B, Barbosa M, Ferreira M, Fiatcoski F, et al.
Behav Pharmacol
. 2024 Dec;
36(1):1-15.
PMID: 39718050
Opioid use disorder is a public health problem that includes symptoms such as withdrawal syndrome and opioid-induced hyperalgesia. Currently, drugs to treat side effects of opioids also have undesirable effects,...
2.
Simei J, de Souza J, Lisboa J, Guimaraes F, de Souza Crippa J
Int Rev Neurobiol
. 2024 Jul;
177:205-234.
PMID: 39029985
Anxiety disorders are highly prevalent psychiatric disorders, characterized by a chronic course and often accompanied by comorbid symptoms that impair functionality and decrease quality of life. Despite advances in basic...
3.
Arantes A, Carvalho M, Brandao M, Prado W, de Souza Crippa J, Lovick T, et al.
Behav Brain Res
. 2023 Dec;
459:114793.
PMID: 38048909
This study investigated the antinociceptive potential of cannabidiol (CBD) in male and female Wistar rats. The assessment and analysis included tail withdrawal to thermal stimulation (tail flick test) and mechanical...
4.
Loureiro S, Zuardi A, Silveira I, de Souza Crippa J, Hallak J, Osorio F
Front Psychiatry
. 2023 Nov;
14:1237123.
PMID: 38025454
Introduction: Even though the long-term effects of the COVID-19 pandemic on healthcare workers' mental health remain unknown, such effects might negatively impact health services and patient safety, especially in countries...
5.
Osorio F, Zuardi A, Silveira I, de Souza Crippa J, Hallak J, Pereira-Lima K, et al.
Front Psychiatry
. 2023 Apr;
14:1026429.
PMID: 37032945
This study aimed to: (a) monitor the progression of symptoms of mental health burden among frontline workers caring for COVID-19 patients in Brazil during the two waves of the pandemic,...
6.
Chaves Y, Raymundi A, Waltrick A, de Souza Crippa J, Stern C, Cunha J, et al.
Acta Neuropsychiatr
. 2023 Feb;
36(5):276-286.
PMID: 36805056
Objectives: In view of the neuroprotective characteristic of cannabidiol (CBD) and its beneficial action on aversive memory in non-diabetic animals, we aimed to investigate in animals with experimentally induced type-1...
7.
Cruz J, Rosa M, Mores L, Carasek E, de Souza Crippa J, Figueiredo E, et al.
Anal Chim Acta
. 2022 Sep;
1226:340160.
PMID: 36068070
This manuscript describes the development of magnetic restricted-access carbon nanotubes (M-RACNTs) for use as SPME sorbent to determine cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) in human plasma samples by UHPLC-MS/MS. The...
8.
Jesus C, Ferreira M, Gasparin A, Rosa E, Genaro K, de Souza Crippa J, et al.
Behav Brain Res
. 2022 Aug;
435:114076.
PMID: 36028000
Neuropathic pain (NP) is a complex health problem that includes sensorial manifestations such as evoked and ongoing pain. Cannabidiol (CBD) has shown potential in the treatment of NP and the...
9.
de Almeida C, Brito M, Bosaipo N, Pimentel A, Sobreira-Neto M, Tumas V, et al.
Cannabis Cannabinoid Res
. 2022 Jun;
8(2):374-378.
PMID: 35749710
Cannabidiol (CBD) is one of the main nonpsychoactive components of and may represent an alternative treatment for Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) in patients with Parkinson's disease (PD) and REM...
10.
Poli-Neto O, Hallak J, Rosa-E-Silva J, de Souza Crippa J
Rev Bras Ginecol Obstet
. 2022 Jun;
44(5):449-451.
PMID: 35697067
No abstract available.